Abstract YO31
Case summary
A 66-year-old male presented with left-sided pleuritic chest pain, common weak for 2 months and progressively increasing shortness of breath with dry cough for 1.5 months.On general survey, mild pallor was present, but there were no clubbing and palpable cervical and axillary lymph node. An X-ray showed a shadow in the left chest. The shadow of the heart was shifted to the right. Bronchoscopy showed compression of segmental bronchus of the left upper lobe bronchus. CT of the chest reveals a nodular pleura-based mass, which size was about 12.5х18.0х18.0 sm with effusion in the left pleural cavity. Around the nodular pleura-based mass were infiltrative changens. The histological analysis of tru-cut biopsy showed that there was fibrotic mesothelioma with necrosis or carcinoid. The patient underwent right upper lobectomy of lung with negative margins. During operation we saw that half of left pleural cavity was occupied by gigantic tumor, which size was 25x20x18 sm. Surface was bumpy, it had capsule, thick texture. There were effusion (150ml) in the left pleural cavity. The root of the lung, pericardium, thoracic part of aorta, diaphragm were free. The tumor was grew from right upper lobe (S5). The histological analysis after operation of this tumor showed that it was round cell sarcoma. After surgery, six cycles of adjuvant chemotherapy with ifosfamide and doxorubicin were given. Postadjuvant chemotherapy patient is kept on regular follow-up.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract